[go: up one dir, main page]

AR018186A1 - Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto - Google Patents

Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto

Info

Publication number
AR018186A1
AR018186A1 ARP990101770A ARP990101770A AR018186A1 AR 018186 A1 AR018186 A1 AR 018186A1 AR P990101770 A ARP990101770 A AR P990101770A AR P990101770 A ARP990101770 A AR P990101770A AR 018186 A1 AR018186 A1 AR 018186A1
Authority
AR
Argentina
Prior art keywords
compounds
spla2
carbazoly
tetrahydrocarbazol
inhibitors
Prior art date
Application number
ARP990101770A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR018186A1 publication Critical patent/AR018186A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se trata de nuevos compuestos tricíclicos de aplicacion en la inhibicion de la liberacion de ácidos grasos mediada por sPLA2, tal como el choque séptico.Dichos compuestos responden a las formulas (I) y (II) donde: Z es ciclohexenilo o fenilo; R21 esun sustituyente no interferente; R21 es un grupo -NHNH2 y R2es un grupo hidroxilo o -O(CH2)mR5, donde R5 tiene los valores indicados en la descripcion. También se reivindican los objetivos mencionados en el título de lasolicitud.
ARP990101770A 1998-04-17 1999-04-16 Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto AR018186A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
AR018186A1 true AR018186A1 (es) 2001-10-31

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990101770A AR018186A1 (es) 1998-04-17 1999-04-16 Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto
ARP990101771A AR018593A1 (es) 1998-04-17 1999-04-16 COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADAS

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP990101771A AR018593A1 (es) 1998-04-17 1999-04-16 COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADAS

Country Status (30)

Country Link
EP (2) EP0950657B1 (es)
JP (2) JP4435330B2 (es)
KR (2) KR100586761B1 (es)
CN (1) CN1149193C (es)
AR (2) AR018186A1 (es)
AT (2) ATE271037T1 (es)
AU (2) AU753547B2 (es)
BR (2) BR9901279A (es)
CA (2) CA2269262A1 (es)
CO (2) CO5011054A1 (es)
CZ (2) CZ137099A3 (es)
DE (2) DE69918590T2 (es)
DK (1) DK0950657T3 (es)
DZ (1) DZ2769A1 (es)
EA (2) EA002816B1 (es)
ES (2) ES2226286T3 (es)
HU (2) HUP9901221A3 (es)
ID (2) ID23287A (es)
IL (2) IL129483A0 (es)
NO (2) NO314400B1 (es)
NZ (3) NZ335251A (es)
PE (2) PE20000432A1 (es)
PL (2) PL332566A1 (es)
PT (1) PT950657E (es)
SG (2) SG81977A1 (es)
SI (1) SI0950657T1 (es)
TR (2) TR199900843A2 (es)
TW (1) TWI238160B (es)
YU (2) YU19199A (es)
ZA (2) ZA992772B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610728B2 (en) * 1997-08-28 2003-08-26 Eli Lilly And Company Method for treatment of non-rheumatoid arthritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
AU1940800A (en) * 1998-12-21 2000-07-12 Eli Lilly And Company Combination therapy for the treatment of sepsis
WO2001005761A1 (en) * 1999-07-19 2001-01-25 Eli Lilly And Company sPLA2 INHIBITORS
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
US6967200B2 (en) 2000-06-29 2005-11-22 Shionogi & Co., Ltd. Remedies for cirrhosis
US20040102442A1 (en) * 2000-06-29 2004-05-27 Kohji Hanasaki Remedies for alzheimer's disease
EP1300159B1 (en) * 2000-06-29 2007-10-10 Anthera Pharmaceuticals, Inc. Remedies for cancer
CA2413582A1 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
WO2002050034A2 (en) * 2000-12-18 2002-06-27 Eli Lilly And Company Tetracyclic carbazole derivates and their use as spla2 inhibitors
ATE353876T1 (de) * 2001-03-28 2007-03-15 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
CN101981012A (zh) 2008-03-26 2011-02-23 第一三共株式会社 新的四氢异喹啉衍生物
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
EP2379538A4 (en) 2009-01-22 2013-01-02 Orchid Res Lab Ltd HETEROCYCLIC COMPOUNDS AS A PHOSOPHODIESTERASE HEMMER
JP2012523424A (ja) 2009-04-07 2012-10-04 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼの阻害薬
AU2010234449A1 (en) 2009-04-07 2011-11-03 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
CA2788587C (en) 2010-02-03 2020-03-10 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
WO2014083113A1 (en) 2012-11-30 2014-06-05 Ge Healthcare Limited Crystallization process of tricyclic indole derivatives
JP2016501211A (ja) * 2012-11-30 2016-01-18 ジーイー・ヘルスケア・リミテッド 三環性インドールを得るためのハロゲン化亜鉛による環化プロセス
WO2016116527A1 (de) * 2015-01-20 2016-07-28 Cynora Gmbh Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
CA2110514A1 (en) * 1991-07-05 1993-01-21 Raymond Baker Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
ES2151993T3 (es) * 1995-06-23 2001-01-16 Lilly Co Eli 1,2,3,4-tetrahidro-9h-carbazoles 6-sustituidos y 10h-ciclohepta(7,6-b)indoles 7-sustituidos.
ES2159347T3 (es) * 1995-12-13 2001-10-01 Lilly Co Eli Naftil-acetamidas como inhibidores de spla2.
BR9713261A (pt) * 1996-10-30 2000-03-28 Lilly Co Eli Tricìclicos substituìdos
EP1007056A1 (en) * 1997-09-26 2000-06-14 Eli Lilly And Company Method for the treatment of cystic fibrosis
EP1043991A4 (en) * 1997-11-14 2005-02-02 Lilly Co Eli TREATMENT OF ALZHEIMER DISEASE
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
EA002816B1 (ru) 2002-10-31
EP0950657B1 (en) 2004-07-14
ID23761A (id) 2000-05-11
JPH11322713A (ja) 1999-11-24
NZ335251A (en) 2000-11-24
AU753436B2 (en) 2002-10-17
CA2269246A1 (en) 1999-10-17
NZ507564A (en) 2002-10-25
EP0952149A3 (en) 2001-08-16
TR199900853A3 (tr) 1999-11-22
AU753547B2 (en) 2002-10-24
DE69918590T2 (de) 2005-07-21
HU9901221D0 (en) 1999-06-28
SG81977A1 (en) 2001-07-24
ATE271037T1 (de) 2004-07-15
PL332565A1 (en) 1999-10-25
AU2381999A (en) 1999-10-28
ID23287A (id) 2000-04-05
AR018593A1 (es) 2001-11-28
EP0952149A2 (en) 1999-10-27
JP2000026416A (ja) 2000-01-25
IL129483A0 (en) 2000-02-29
EA199900301A2 (ru) 1999-10-28
NO991822D0 (no) 1999-04-16
PT950657E (pt) 2004-11-30
NO991822L (no) 1999-10-18
NO314400B1 (no) 2003-03-17
EA199900301A3 (ru) 2000-04-24
EA002347B1 (ru) 2002-04-25
CZ137099A3 (cs) 1999-11-17
DE69918590D1 (de) 2004-08-19
NO312240B1 (no) 2002-04-15
SI0950657T1 (en) 2005-02-28
DE69917833T2 (de) 2005-07-14
TR199900853A2 (xx) 1999-11-22
BR9902365A (pt) 2001-04-24
NO991821L (no) 1999-10-18
CN1253948A (zh) 2000-05-24
HUP9901221A3 (en) 2001-11-28
TR199900843A2 (xx) 2000-02-21
PE20000432A1 (es) 2000-05-23
CA2269262A1 (en) 1999-10-17
HUP9901220A3 (en) 2001-11-28
YU19199A (sh) 2002-08-12
EP0950657A3 (en) 2001-08-16
ZA992772B (en) 2002-07-16
EP0952149B1 (en) 2004-06-09
KR19990083233A (ko) 1999-11-25
KR100586761B1 (ko) 2006-06-08
KR19990083232A (ko) 1999-11-25
CA2269246C (en) 2009-08-25
EA199900303A2 (ru) 1999-10-28
DE69917833D1 (de) 2004-07-15
EA199900303A3 (ru) 2000-04-24
IL129485A0 (en) 2000-02-29
TWI238160B (en) 2005-08-21
ES2222663T3 (es) 2005-02-01
ZA992771B (en) 2002-04-18
HU9901221A (hu) 2000-04-28
HU9901220D0 (en) 1999-06-28
CN1149193C (zh) 2004-05-12
CZ136999A3 (cs) 1999-11-17
CO5011054A1 (es) 2001-02-28
JP4435330B2 (ja) 2010-03-17
PE20000476A1 (es) 2000-06-02
ATE268756T1 (de) 2004-06-15
ES2226286T3 (es) 2005-03-16
PL332566A1 (en) 1999-10-25
DZ2769A1 (fr) 2003-12-01
NO991821D0 (no) 1999-04-16
EP0950657A2 (en) 1999-10-20
AU2381799A (en) 1999-10-28
SG81976A1 (en) 2001-07-24
HU9901220A (hu) 2000-04-28
CO5031247A1 (es) 2001-04-27
BR9901279A (pt) 2000-05-02
NZ335253A (en) 2000-11-24
DK0950657T3 (da) 2004-11-22
YU18999A (sh) 2002-08-12

Similar Documents

Publication Publication Date Title
AR018186A1 (es) Compuestos de carbazoly de 1,2,3,4-tetrahidrocarbazol sustituidos, utiles como inhibidores de la liberacion de acidos grasos mediada por spla2,procedimiento para prepararlos; compuestos intermediarios de aplicacion en dichos procedimientos; composiciones farmaceuticas que comprenden dichos compuesto
GT199900115A (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
PE25198A1 (es) Nuevos taxoides, su preparacion y las composiciones farmaceuticas que las contienen
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
UY25204A1 (es) Agonistas de prostaglandinas útiles en el tratamiento de desórdenes óseos
RU95104885A (ru) 1h-индол-3-глиоксиламиды, ингибирующие spla2-медируемое выделение жирных кислот, фармацевтическая композиция
UY28878A1 (es) Compuestos de aril-o heteroarilamida ortosustituidos y composiciones
PE44599A1 (es) Inhibidores de la enzima acido nitrico sintasa
AR013494A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
CO5021213A1 (es) INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-k8
PE107999A1 (es) Derivados 3-amidinoanilina, inhibidores del factor x de coagulacion de la sangre activado e intermediarios de los mismos
ES2193874B1 (es) Compuestos naturales y derivados de estos para la prevencion y el tratamiento de enfermedades cardiovasculares, hepaticas, renales y cosmeticas.
ES2179823T3 (es) Inmunosupresor macrolido.
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
AR009358A1 (es) Compuesto espirociclico inhibidor de la metaloproteasa
TR199900956T2 (xx) S�bstit�e edilmi� trisiklik bile�imler.
MX173310B (es) Derivados fenolicos de benzotiazol como inhibidores de la corrosion
ES2159347T3 (es) Naftil-acetamidas como inhibidores de spla2.
MX9305364A (es) Compuestos inhibidores de proteasa retroviral, metodo para su produccion y composicion farmaceutica que los comprende.
NO20013100D0 (no) Sulfonamidhydroksamater
CO5011061A1 (es) Inhibicion de las metaloprotesas de matriz por acidos biariloxobutiricos sustituidos y composiciones farmaceuticas que los contienen
MX9304399A (es) Proceso novedoso para preparar [[2-bromoetil)-amino]metil]-2-nitro-1h-imidazol-1-etanol quiral y compuestos relacionados.
EA199900304A2 (ru) Замещенные трициклические соединения
AR040763A1 (es) Profarmacos de la (n-2- piridil-n-2- hidroxicarbonil-etil) - amida del acido 1- metil-2-(4-amidinofenilaminometil)-- benzimidazol-5-il-carboxilico, su preparacion y su utilizacion como medicamentos
BR0012242A (pt) Composição de óleo para máquina de refrigeração

Legal Events

Date Code Title Description
FA Abandonment or withdrawal